Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group..

Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25.

PMID:
21108561
2.

Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.

Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D.

Coron Artery Dis. 2009 May;20(3):219-24. doi: 10.1097/MCA.0b013e3283219e47.

PMID:
19322079
3.
4.

Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.

Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J.

Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7.

PMID:
23294528
5.

Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome.

Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH.

Circ J. 2006 Nov;70(11):1379-84.

6.
7.

Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.

Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J.

Coron Artery Dis. 2012 Mar;23(2):91-7. doi: 10.1097/MCA.0b013e32834f1165.

PMID:
22157356
8.

Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.

Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group..

Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30.

PMID:
23723326
9.

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR.

J Hypertens. 2006 Aug;24(8):1531-9.

PMID:
16877955
11.

Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.

Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, Morrow DA.

Eur Heart J. 2011 Mar;32(6):697-705. doi: 10.1093/eurheartj/ehq468. Epub 2010 Dec 22.

PMID:
21183500
12.

N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L.

J Am Coll Cardiol. 2003 Dec 3;42(11):1909-16.

13.

N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR.

Eur Heart J. 2007 Jun;28(11):1374-81. Epub 2007 Jan 22.

PMID:
17242007
14.

N-terminal pro B-type natriuretic peptide identifies patients with chest pain at high long-term cardiovascular risk.

van der Zee PM, Cornel JH, Bholasingh R, Fischer JC, van Straalen JP, De Winter RJ.

Am J Med. 2011 Oct;124(10):961-9. doi: 10.1016/j.amjmed.2011.05.026.

PMID:
21962317
15.

N-terminal pro-B-type natriuretic Peptide predicts significant coronary artery lesion in the unstable angina patients with normal electrocardiogram, echocardiogram, and cardiac enzymes.

Hong SN, Yoon NS, Ahn Y, Lim SY, Kim YS, Yun KH, Kang DK, Lee SH, Lee YS, Kim KH, Son IS, Hong YJ, Park HW, Kim JH, Jeong MH, Cho JG, Park JC, Kang JC.

Circ J. 2005 Dec;69(12):1472-6.

16.

The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.

West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino C, Lubos E, Münzel TF, White HD, Tonkin AM, Bickel C, Tiret L, Blankenberg S; LIPID Study Investigators..

Eur Heart J. 2008 Apr;29(7):923-31. doi: 10.1093/eurheartj/ehn007. Epub 2008 Feb 22.

PMID:
18296678
17.

Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW.

Circulation. 2005 Jul 5;112(1):110-6. Epub 2005 Jun 27.

18.

Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.

Delhaye C, Sudre A, Lemesle G, Maréchaux S, Broucqsault D, Hennache B, Bauters C, Lablanche JM.

Cardiovasc Revasc Med. 2009 Jul-Sep;10(3):144-50. doi: 10.1016/j.carrev.2009.01.005.

PMID:
19595394
19.

Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.

Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL.

Eur Heart J. 2009 May;30(9):1057-65. doi: 10.1093/eurheartj/ehn600. Epub 2009 Jan 23.

PMID:
19168526

Supplemental Content

Support Center